Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The primary efficacy endpoint will be the proportion of subjects that remain free of
progression at the 27th week following the onset of treatment. Secondary objectives include
the subject's time in weeks from treatment onset to documented disease progression as
assessed by the RECIST criteria, response rate, median and overall survival, safety and
tolerability.